Traws Pharma, Inc. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value
Traws Pharma, Inc. (TRAW) had Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value of $44.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Notes › Fair Value Disclosures
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue · last filed 2026-08-14
- 2026-06-30: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value $44.00K.
- 2026-03-31: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value $259.00K.
- 2025-12-31: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value $100.00K.
- 2025-09-30: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value $11.00K.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value |
|---|---|
| 2026-06-30 | $44.00K 10-Q · filed 2026-08-14 |
| 2026-03-31 | $259.00K 10-Q · filed 2026-08-14 |
| 2025-12-31 | $100.00K 10-Q · filed 2026-08-14 |
| 2025-09-30 | $11.00K 10-Q · filed 2025-11-13 |
| 2025-06-30 | $8.00K 10-Q · filed 2025-11-13 |
| 2025-03-31 | $154.00K 10-Q · filed 2025-11-13 |
| 2024-12-31 | $42.49M 10-K · filed 2026-04-15 |
| 2018-09-30 | $1.00K 10-Q · filed 2018-11-14 |
| 2018-06-30 | $1.00K 10-Q · filed 2018-11-14 |
| 2018-03-31 | $4.00K 10-Q · filed 2018-11-14 |
| 2017-12-31 | $18.00K 10-K · filed 2019-04-01 |
| 2017-09-30 | $27.00K 10-Q · filed 2017-11-09 |
| 2017-06-30 | $40.00K 10-Q · filed 2017-11-09 |
| 2017-03-31 | $4.95M 10-Q · filed 2017-11-09 |
| 2016-12-31 | $3.40M 10-K · filed 2019-04-01 |
| 2016-09-30 | $4.41M 10-Q · filed 2016-11-14 |
| 2016-06-30 | $287.00K 10-Q · filed 2016-08-15 |
| 2016-03-31 | $295.00K 10-Q · filed 2016-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |